专访凯西集团中国总裁兼总经理邓浩青：博鳌乐城“先行先试”政策是一场双向奔赴 能提高药物可及性

Core Viewpoint - The introduction of the innovative drug FILSUVEZ for Epidermolysis Bullosa (EB) patients in China marks a significant breakthrough in addressing the treatment gap for this rare genetic skin disease, facilitated by the "pilot" policy in Boao Lecheng [1][2][3] Group 1: Drug Introduction and Significance - FILSUVEZ is the first drug approved for treating nutritional deficiency type (DEB) and junctional type (JEB) EB wounds in patients aged six months and older, receiving approvals from EMA and FDA in June 2022 and December 2023 respectively [2] - The drug's availability in Boao Lecheng allows patients to access treatment that was previously unavailable in China, addressing a critical need for EB patients [3][4] - The introduction of FILSUVEZ is expected to create a viable pathway for the registration and market entry of innovative drugs in China, as it provides real-world data for future regulatory processes [3][5] Group 2: Collaboration and Policy Impact - The collaboration between the Cassi Group and Boao Lecheng was initiated to expedite the introduction of urgently needed innovative drugs, with both parties sharing a common goal [2][3] - The "pilot" policy in Boao Lecheng allows for the early use of foreign-approved drugs, which helps patients receive treatment sooner while also aiding regulatory assessments based on real-world data [4][5] Group 3: Market Dynamics and Future Strategy - The changing landscape of the Chinese pharmaceutical industry is prompting multinational companies to adapt, focusing on innovation and addressing unmet medical needs [6][8] - The Cassi Group aims to enhance its presence in China, with a growth strategy that includes local market needs and potential future product introductions [6][7] - The company reported a 22% revenue growth in China last year, indicating the market's significance in its global operations, with aspirations to rank among the top five markets globally in the next decade [8]